Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 3 2Phase 2 2Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Non-Small-Cell Lung 23Breast Neoplasms 22Colorectal Neoplasms 14Ovarian Neoplasms 12Lung Neoplasms 10Neoplasm Metastasis 9Stomach Neoplasms 8Neoplasms 8Nasopharyngeal Carcinoma 8Leukemia, Myeloid, Acute 7Triple Negative Breast Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Rectal Neoplasms 6Fallopian Tube Neoplasms 6Recurrence 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Esophageal Squamous Cell Carcinoma 5Uterine Cervical Neoplasms 4Prostatic Neoplasms 4Lymphoma, Non-Hodgkin 4Leukemia 4Head and Neck Neoplasms 4Esophageal Neoplasms 4Carcinoma, Ovarian Epithelial 4Pancreatic Neoplasms 3Neoplasms by Site 3Lymphoma, Large B-Cell, Diffuse 3Adenocarcinoma 3Urinary Bladder Neoplasms 2Multiple Myeloma 2

Interventions

Gemcitabine 28Cisplatin 26Mitomycin 18BCG Vaccine 12pembrolizumab 9Paclitaxel 8Doxorubicin 7Docetaxel 75-aminolevulinic acid hexyl ester 7apaziquone 6Carboplatin 6vinflunine 5enfortumab vedotin 5atezolizumab 5Vinblastine 5Radiotherapy 5Methotrexate 5Magnetic Resonance Spectroscopy 5Fluorouracil 5Cystectomy 5durvalumab 4Surgical Procedures, Operative 4Nivolumab 4Transurethral Resection of Bladder 3Specimen Handling 3Selenium 3Radiation 3Filgrastim 3Cystoscopy 3BCG Connaught 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Urinary Bladder Neoplasms × Drug Therapy × Clear all
NCT07419295 2026-05-29

TroFuse-031

Merck Sharp & Dohme LLC

Phase 3 Recruiting
590 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT03661320 2026-04-15

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

Bristol-Myers Squibb

Phase 3 Active not recruiting
855 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡